Health-related quality of life and cost comparison of adjuvant capecitabine versus 5-fluorouracil/leucovorin in stage III colorectal cancer patients

NCUIR > college of Health Sciences and Technology > Department of Biomedical Sciences and Engineering > journal & Dissertation > Item 987654321/102762

Please use this identifier to cite or link to this item: https://ir.lib.ncu.edu.tw/handle/987654321/102762

Title:	Health-related quality of life and cost comparison of adjuvant capecitabine versus 5-fluorouracil/leucovorin in stage III colorectal cancer patients
Authors:	李興中;Chen, Hong-Hwa;Chen, William Tzu-Liang;Lee, Hsin-Chung;Lin, Jen-Kou;Fang, Chuan-Yin;Chou, Yenn-Hwei;Lin, Peng-Chan;Lin, Bo-Wen;Huang, Chi-Chou;Yeh, Chung-Hung;Hsu, Hsi-Hsien;Chen, Hung-Chang;Ting, Wen-Chien;Yang, Ming-Chin;Tan, Elise Chia-Hui
Contributors:	生醫理工學院生醫科學與工程學系
Keywords:	Adjuvants;Adult;Aged;Antimetabolites, Antineoplastic - economics;Antimetabolites, Antineoplastic - therapeutic use;Antineoplastic Combined Chemotherapy Protocols - economics;Antineoplastic Combined Chemotherapy Protocols - therapeutic use;Cancer therapies;Capecitabine;Chemotherapy;Chemotherapy, Adjuvant;CLINICAL AND POLICY APPLICATIONS;Clinical outcomes;Colorectal cancer;Colorectal Neoplasms - drug therapy;Colorectal Neoplasms - pathology;Colorectal surgery;Cost analysis;Cost-Benefit Analysis;Deoxycytidine - analogs & derivatives;Deoxycytidine - economics;Deoxycytidine - therapeutic use;Female;Fluorouracil - analogs & derivatives;Fluorouracil - economics;Fluorouracil - therapeutic use;Health insurance;Health Status;Hospitals;Humans;Leucovorin - economics;Leucovorin - therapeutic use;Male;Medical prognosis;Medicine;Medicine & Public Health;Middle Aged;Mortality;National health insurance;Oncology;Patients;Population;Prospective Studies;Public Health;Quality of Life;Quality of Life Research;Sociology;Studies;Surveys and Questionnaires
Date:	2015-02-01
Issue Date:	2026-04-23 11:16:15 (UTC+8)
Publisher:	Springer Netherlands;Cham: Springer
Abstract:	摘要： Purpose The purpose of this study was to compare health-related quality of life (HRQoL) and costs associated with 2 adjuvant chemotherapy regimens [capecitabinebased therapy versus 5-fluorouracil/leucovorin (5-FU/LV)-based therapy] in stage III colorectal cancer patients. Methods We conducted a prospective, open-label, observational, multicenter study from July 2008 to July 2011. The European Organization for Research and Treatment of Cancer QLQ-C30 and QLQ-CR38 questionnaires was used to assess HRQoL before, during, and after treatment. The direct and indirect costs of adjuvant treatment were estimated from a specially prepared questionnaire, the National Health Insurance Research Database, and other published sources. We used propensity scoring to match samples between groups and performed multivariate analyses to adjust for differences in patient demographics and clinical characteristics. Results A total of 497 patients were enrolled, and 356 completed the surveys. Following propensity score matching, 239 patients were included in the analysis (122 in the capecitabine-based group, 117 in the 5-FU/LV-based group). Global HRQoL scores did not differ significantly between the two groups. However, compared to patients in the 5-FU/LV-based group, patients in the capecitabine-based group had less nausea and vomiting (mid-term, P = 0.024; final, P = 0.013), appetite loss (mid-term, P< 0.0001; final, P = 0.001), and fewer side effects from chemotherapy (mid-term, P = 0.017). In addition, the monthly cost of capecitabine-based therapy was lower than those of 5-FU/ LV-based therapy [NT$31,895.46 (US$1063.18) vs. NT$79,159.24 (US$2638.64) per patient]. Conclusions Capecitabine is a reasonable alternative and cost-effective treatment option under current conditions for patients with stage III colorectal cancer. 其他題名： Qual Life Res 出版者： Cham: Springer 出版日期： 2015-02-01 出處： Quality of life research, 2015-02, Vol.24 (2), p.473-484 資源來源： JSTOR Arts and Sciences VII 版權： Springer International Publishing 2015 版權： Springer International Publishing Switzerland 2014 版權： Springer International Publishing Switzerland 2015 識別號： ISSN: 0962-9343 識別號： ISSN: 1573-2649 識別號： EISSN: 1573-2649 識別號： DOI: 10.1007/s11136-014-0773-x 識別號： PMID: 25099199
Appears in Collections:	[Department of Biomedical Sciences and Engineering ] journal & Dissertation

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	14	View/Open

社群 sharing

Loading...